Tests an SGLT2 inhibitor after heart rhythm restoration in persistent atrial fibrillation with HFpEF
Tests dapagliflozin or empagliflozin after cardioversion in adults with atrial fibrillation and heart failure.
Plain-language title generated from the registry record
Registry title: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 4
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT07776054
- Record updated
- 20 August 2026
- Original description
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.Read full original descriptionShow less
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Inclusion: Age ≥19 years; Persistent atrial fibrillation; H2FPEF score ≥6 or HFA-PEFF score ≥5; Restoration of sinus rhythm after electrical cardioversion.
Exclusion: Previous use of an SGLT2 inhibitor; Intracardiac thrombus on transesophageal echocardiography; Refusal to participate.